Changes in Hong Kong stocks | JD Health (06618) rises nearly 4% in early trading, the peak of influenza hits, and the company's demand for influenza detection reagents and children's cold medicines is rising

The Zhitong Finance App learned that JD Health (06618) rose nearly 4% in early trading. As of press release, it had risen 3.19% to HK$63, with a turnover of HK$149 million.

According to news, recently, according to Arterial Network reports, with the arrival of the peak of influenza in various regions, demand for respiratory infectious disease testing has risen. JD Health Data shows that sales of influenza test kits have increased dramatically, and multiple test kits have become a new trend. In order to respond to demand, JD Health co-brand merchants launched a special guarantee mechanism to ensure stable supply without price increases. Its medical device department cooperated with several brands and companies to establish IVD brand alliances last month to predict demand in advance and prepare stocks scientifically. At the same time, JD Health upgraded the time limit for contract delivery, as fast as half an hour in some regions.

On the other hand, JD Health recently exclusively launched Cowell ^® oseltamivir granules in a 15mg x 18 bag treatment package, which accurately focuses on the pain points of “mismatched doses and easy drug waste” in the treatment of influenza in children. The specification is based on a 5-day standard course of treatment, which can cover the full cycle of medication for children over 1 year old and weighing less than 15 kg, achieving “one drug purchase, covering the entire course of treatment”, greatly simplifying parents' medication preparation and medication usage procedures, and effectively avoiding drug waste. Since its launch, the average daily turnover of this product has grown by more than 100%, making it the first choice for many households to prepare influenza medicine.